Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK meets main endpoint in oral gonorrhea treatment trial
11:00am, Monday, 26'th Feb 2024
GSK has hailed the results from a late-stage trial of a new oral antibiotic for gonorrhoea, which met its primary endpoint of at last matching the current standard treatments. Chris Corsico, senior vi
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
10:46am, Monday, 26'th Feb 2024
Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
GSK's gonorrhoea drug meets primary goal in late-stage trial
02:03am, Monday, 26'th Feb 2024
British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.
This pharma stock surged 13% in a day
04:14am, Friday, 23'rd Feb 2024
Moderna (NASDAQ: MRNA) stock significantly surged on February 22 after the company surpassed Wall Street's quarterly expectations.
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth
02:00pm, Wednesday, 21'st Feb 2024
Good dividend stocks provide their owners with reliable income. What's more, even if these equities drop, investors are “paid to wait” for them to rebound down the road.
First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says
06:21am, Wednesday, 21'st Feb 2024
British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progressi
GSK's injectable HIV drug shows promise over daily pills
03:17am, Wednesday, 21'st Feb 2024
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing ch
DivHut Dividend Income Update: January 2024
07:30am, Friday, 16'th Feb 2024
DivHut Dividend Income Update: January 2024
GSK acquires respiratory firm Aiolos Bio for US$1.4 billion
05:01am, Thursday, 15'th Feb 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced the US$1.4 billion acquisition of respiratory biopharmaceuticals firm Aiolos Bio. FTSE 100-listed GSK said the takeover, which will se US$1 billion paid upfro
GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy
02:45am, Thursday, 15'th Feb 2024
GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
02:41am, Thursday, 15'th Feb 2024
GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.
Hedge fund snaps up stake in Love Island maker ITV
05:23am, Tuesday, 13'th Feb 2024
A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price
GSK: American investment bank goes positive on the stock for the first time in seven years. Here's why
04:22am, Tuesday, 13'th Feb 2024
The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years. Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 12'th Feb 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK granted US fast track status for chronic hepatits B treatment
02:37am, Monday, 12'th Feb 2024
GSK has been granted US Fast Track designation for bepirovirsen, an investigational treatment for chronic hepatitis B (CHB). A request was made to US regulator the FDA by the UK pharma due to an un
